The exhibition hall of Wuhan Loongvision Co in WEDZ. [Photo/WeChat account: whkfq]
Wuhan Loongvision Co in Wuhan Economic & Technological Development Zone (WEDZ) has announced that its innovative puncture surgery navigation device has been approved by the National Medical Products Administration (NMPA).
A representative from Loongvision highlighted the significance of this development, saying that the device incorporates cutting-edge deep learning software. "This approval marks a significant advancement for domestic AI technology, allowing for a transition from 'diagnostic assistance' to 'therapeutic assistance' in clinical treatment," the representative noted.
The navigation robot is designed for lung and abdominal puncture surgeries, functioning as a 'smart eye' for physicians. It analyzes preoperative CT images to accurately identify critical structures such as blood vessels and organs.
The system then calculates the optimal puncture path to avoid vital tissues, guiding the needle to the target with a precision error margin of less than 1 millimeter," said a company researcher.
A standout feature of the navigation robot is its reusable core sensor, which is compatible with various puncture needles, ensuring surgical precision and reducing consumable costs per procedure.
Loongvision, founded in 2023, is a subsidiary of InferVision, a global leader in AI medical technology.
WEDZ has been expanding its healthcare industry in recent years, now hosting over 130 pharmaceutical companies, including notable ones such as CR Pharma and Hiteck Biopharmaceutical.
